GlassScriptPhysician profile
Charles Vaden Terry
NPI 1184652919
$2,423.86
in general payments reported to CMS, 2019-2025
23 companies · $249 in 2025
The $249 reported for 2025 was more than what 80% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $136 · 2021: $291 · 2022: $435 · 2023: $370 · 2024: $576 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $577.90 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $412.18 | 2021-2025 | Qelbree |
| Corium, LLC | $322.60 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $188.06 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $173.02 | 2019-2022 | |
| Tris Pharma INC | $119.10 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $104.93 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $72.20 | 2020-2025 | Elaprase |
| Neos Therapeutics, LP | $63.25 | 2019 | |
| Sanofi Pasteur INC. | $61.32 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $49.53 | 2021-2024 | Gardasil 9, Rotateq, Gardasil |
| Cranial Technologies, INC | $47.29 | 2022-2023 | Doc Band |
| Genentech USA, INC. | $43.76 | 2019-2020 | |
| Seqirus USA INC | $32.40 | 2021-2023 | Flucelvax Quadrivalent |
| Shire North American Group INC | $28.84 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.69 | 2025 | Pediarix, Bexsero |
| Verrica Pharmaceuticals INC. | $20.57 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $17.86 | 2024 | Fasenra |
| Vertical Pharmaceuticals, LLC | $17.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.53 | 2019 | |
| Photonicare INC | $13.46 | 2025 | Otosight Middle Ear Scope |
| Adlon Therapeutics L.P. | $12.68 | 2020 | |
| Phadia US INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.